A point-by-point response to recent arguments against the use of statins in primary prevention: This statement is endorsed by the American society for preventive cardiology

Clinical Cardiology

Volumn 35, Issue 7, 2012, Pages 404-409

  Joshi, Parag H ^a   Chaudhari, Sameer ^a   Blaha, Michael J ^a   Jones, Steven R ^a   Martin, Seth S ^a   Post, Wendy S ^a   Cannon, Christopher P ^b   Fonarow, Gregg C ^c   Wong, Nathan D ^d   Amsterdam, Ezra ^e   Hirshfeld Jr , John W ^f   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

AMNESIA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIETARY INTAKE; DRUG EFFICACY; DRUG USE; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; MORTALITY; MUSCLE WEAKNESS; MYALGIA; PAIN; PHYSICAL ACTIVITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SMOKING CESSATION; STROKE;

EID: 84863464543     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22016     Document Type: Review

References (40)

1. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation. 2010; 121: 586-613.
2. Tabas I, Williams KJ, Boren J., Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116: 1832-1844. (Pubitemid 350287108)
3. Davignon J., Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109: III39-III43. (Pubitemid 38786442)
4. Blumenthal RS, Redberg R., Should healthy people take cholesterol drugs to prevent heart disease? Wall Street Journal January 23, 2012. Retrieved from. Accessed February 1, 2012.
5. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011; 365: 2078-2087.
6. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010; 376: 1670-1681.
7. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009; 338: b2376.
8. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med. 2010; 170: 1024-1031.
9. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;CD004816.
10. Twain M., Chapters from my autobiography. North American Review September 7, 1906. Available at Project Gutenberg, http://www.gutenberg.org. Accessed February 6, 2012.
11. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207.
12. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012; 59: 572-582.
13. Sever PS, Chang CL, Gupta AK, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 2011; 32: 2525-2532.
14. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007; 357: 1477-1486. (Pubitemid 47572633)
15. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial. Lancet. 2011; 378: 2013-2020.
16. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333: 1301-1307.
17. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics - 2012 Update: a report from the American Heart Association. Circulation. 2012; 125: e2-e220.
18. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008; 29: 2625-2633.
19. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long-term cohort study. BMJ. 2008; 337: a2423.
20. Arguedas JA, Perez MI, Wright JM., Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009; CD004349.
21. Redberg R, Katz M, Grady D., Diagnostic tests: another frontier for less is more: or why talking to your patient is a safe and effective method of reassurance. Arch Intern Med. 2011; 171: 619.
22. Redberg RF, Katz M, Grady D., Editor's Note - to make the case - evidence is required: comment on "Making the case for selective use of statins in the primary prevention setting." Arch Intern Med. 2011; 171: 1594.
23. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375: 735-742.
24. Cannon CP., Balancing the benefits of statins versus a new risk-diabetes. Lancet. 2010; 375: 700-701.
25. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006; 114: 2788-2797. (Pubitemid 46018281)
26. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97: 89C-94C.
27. Ford ES, Greenlund KJ, Hong Y., Ideal cardiovascular health and mortality from all causes and diseases of the circulatory system among adults in the United States. Circulation. 2012; 125: 987-995.
28. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998; 280: 2001-2007. (Pubitemid 28562678)
29. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403. (Pubitemid 34437694)
30. Angermayr L, Melchart D, Linde K., Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus - a systematic review of randomized controlled trials. Ann Behav Med. 2010; 40: 49-64.
31. Chiuve SE, McCullough ML, Sacks FM, et al. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation. 2006; 114: 160-167. (Pubitemid 44420748)
32. Peter LJ., Peter's Quotations: Ideas For Our Time. New York, NY: Bantam Books; 1979: 299.
33. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113: 791-798.
34. Taber DR, Chriqui JF, Powell LM, et al. Banning all sugar-sweetened beverages in middle schools: reduction of in-school access and purchasing but not overall consumption. Arch Pediatr Adolesc Med. 2012; 166: 256-262.
35. Lytsy P, Burell G, Westerling R., Cardiovascular risk factor assessments and health behaviours in patients using statins compared to a non-treated population. Int J Behav Med. 2011; doi:10.1007/s12529-011-9157-6.
36. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239. (Pubitemid 38924592)
37. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; 366: 321-329.
38. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011; 124: 146-153.
39. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358: 1336-1345. (Pubitemid 351468410)
40. Blaha MJ, Budoff MJ, DeFilippis AP, et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet. 2011; 378: 684-692.